Last reviewed · How we verify
CDC infusion
At a glance
| Generic name | CDC infusion |
|---|---|
| Sponsor | Okayama University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Cough
- Fatigue
- Nausea
- Constipation
- Asthenia
- Headache
- Dyspnoea
- Arthralgia
- Platelet count decreased
- Diarrhoea
- Pyrexia
- Anemia
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma (PHASE2)
- Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy (PHASE2)
- An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment (PHASE1)
- Effects of LiveSpo X-SECRET in SupportiveTreatment of Vaginitis (NA)
- Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma (PHASE1)
- A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDC infusion CI brief — competitive landscape report
- CDC infusion updates RSS · CI watch RSS
- Okayama University portfolio CI